Malta - engelsk - Medicines Authority

stirling anglian pharmaceuticals ltd hillington park innovation centre, 1 ainslie road, hillington park, glasgow g52 4ru, united - macrogol, sodium chloride, sodium hydrogen, carbonate, potassium chloride - powder for oral solution - macrogol 3350 6.563 gram(s) ; sodium chloride 0.1754 gram(s) ; sodium hydrogen carbonate 0.0893 gram(s) ; potassium chloride 0.0233 gram(s) - drugs for constipation

Irland - engelsk - HPRA (Health Products Regulatory Authority)

novalus healthcare limited - macrogol 3350; sodium bicarbonate; sodium chloride; potassium chloride - powder for oral solution - 13.8 gram(s) - macrogol, combinations

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - mupirocin, quantity: 20 mg/g - ointment - excipient ingredients: macrogol 400; macrogol 3350 - medicianz mupirocin ointment is indicated for the topical treatment of mild impetigo.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mupirocin, quantity: 20 mg/g - ointment - excipient ingredients: macrogol 3350; macrogol 400 - apo-mupirocin is indicated for the topical treatment of mild impetigo.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mupirocin, quantity: 20 mg/g - ointment - excipient ingredients: macrogol 400; macrogol 3350 - mupirocin lupin is indicated for the topical treatment of mild impetigo.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - abiraterone acetate, quantity: 500 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; sodium lauryl sulfate; silicified microcrystalline cellulose; hypromellose; magnesium stearate; silicon dioxide; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - zytiga is indicated in combination with prednisone or prednisolone for the treatment of: ? newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (adt), or ? patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mcrpc) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (adt) or ? patients with mcrpc who have received prior chemotherapy containing a taxane.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - osimertinib mesilate, quantity: 47.7 mg (equivalent: osimertinib, qty 40 mg) - tablet, film coated - excipient ingredients: purified talc; polyvinyl alcohol; hyprolose; iron oxide black; mannitol; titanium dioxide; macrogol 3350; sodium stearylfumarate; iron oxide red; iron oxide yellow; microcrystalline cellulose; purified water - tagrisso is indicated:,? as adjuvant therapy after tumour resection in patients with non-small cell lung cancer (nsclc) whose tumours have activating epidermal growth factor receptor (egfr) mutations, as detected by a validated test.,? for the first-line treatment of patients with locally advanced or metastatic nsclc whose tumours have activating egfr mutations, as detected by a validated test.,? for the treatment of patients with locally advanced or metastatic nsclc that is egfr t790m mutation-positive, as detected by a validated test.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - osimertinib mesilate, quantity: 95.4 mg (equivalent: osimertinib, qty 80 mg) - tablet, film coated - excipient ingredients: iron oxide black; sodium stearylfumarate; polyvinyl alcohol; purified talc; titanium dioxide; iron oxide red; macrogol 3350; mannitol; hyprolose; iron oxide yellow; microcrystalline cellulose - tagrisso is indicated:,? as adjuvant therapy after tumour resection in patients with non-small cell lung cancer (nsclc) whose tumours have activating epidermal growth factor receptor (egfr) mutations, as detected by a validated test.,? for the first-line treatment of patients with locally advanced or metastatic nsclc whose tumours have activating egfr mutations, as detected by a validated test.,? for the treatment of patients with locally advanced or metastatic nsclc that is egfr t790m mutation-positive, as detected by a validated test.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 80 mg; naloxone hydrochloride dihydrate, quantity: 43.6 mg (equivalent: naloxone hydrochloride?, qty 40 mg) - tablet, modified release - excipient ingredients: ethylcellulose; stearyl alcohol; lactose monohydrate; purified talc; magnesium stearate; povidone; titanium dioxide; iron oxide yellow; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - targin modified release tablet is indicated for the management of severe pain where:,- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and,- the pain is opioid-responsive; and,- requires daily, continuous, long term treatment.,targin modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.,targin modified release tablet is not indicated as an as-needed (prn) analgesia,the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,targin is indicated as a second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - oxycodone hydrochloride, quantity: 60 mg; naloxone hydrochloride dihydrate, quantity: 32.7 mg (equivalent: naloxone hydrochloride?, qty 30 mg) - tablet, modified release - excipient ingredients: ethylcellulose; stearyl alcohol; lactose monohydrate; purified talc; magnesium stearate; povidone; titanium dioxide; iron oxide red; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - targin modified release tablet is indicated for the management of severe pain where:,- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and,- the pain is opioid-responsive; and,- requires daily, continuous, long term treatment.,targin modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.,targin modified release tablet is not indicated as an as-needed (prn) analgesia,the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,targin is indicated as a second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.